@article{JTD14812,
author = {Jin Li and Yaoqi Chen and Xiaoshun Shi and Xiaobing Le and Fenglan Feng and Jingyi Chen and Chengzhi Zhou and Yusong Chen and Shuai Wen and Haikang Zeng and Allen M. Chen and Yu Zhang},
title = {A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes},
journal = {Journal of Thoracic Disease},
volume = {9},
number = {8},
year = {2017},
keywords = {},
abstract = {Background: Studies have shown that the ligand of programmed cell death protein 1 (B7-H1, CD274 or PD-L1) is related to lung cancer driver genes. Although studies have examined the association between lung cancer driver gene mutations or expression and PD-L1 expression, the present studies have not been mined the correlation systematically and genome-widely.
Methods: All relevant published PD-L1 articles with driver genes data and the RNA-seq dataset from The Cancer Genome Atlas (TCGA) were analyzed. We performed meta-analysis for data included in the selected literature, and then independently explored the correlation between genes by co-expression analysis of RNA-seq data in the TCGA database.
Results: A sum of 9,934 lung cancer cases were collected from 34 published studies. Higher PD-L1 expression was associated with wild-type epidermal growth factor receptor (EGFR) [odds ratio (OR): 0.68, 95% confidence interval (CI): 0.48–0.96, P=0.03], Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation (OR: 1.27, 95% CI: 1.02–1.58, P=0.03) or non-adenocarcinoma histology (OR: 0.68, 95% CI: 0.47–0.98, P=0.04). In addition, our analysis from TCGA data indicated that, compared with lung adenocarcinoma, the expression of PD-L1 was significantly higher than that of squamous cell carcinoma patients (P=0.023). The expression of targetable driver genes showed no correlations with PD-L1 expression in non-small cell lung cancer (NSCLC).
Conclusions: Our results suggest the presence of EGFR wild-type, KRAS gene mutations or squamous cell carcinoma were associated with high PD-L1expression, which provides potential benefited population for the administration of PD-1/PD-L1 blockade in human lung cancer.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/14812}
}